See you AI Japan announces the addition of a multi-turn output option to the Absolute Encoder series.

Environmentally resistant absolute encoder

The CUI AMT21 series is a robust and high-precision absolute encoder that outputs 12-bit or 14-bit absolute position information with RS-485 communication and single-turn or multi-turn output options. Thanks to its innovative capacitive platform, this series is less susceptible to contaminants (such as dirt, dust, and oil) that encoders are often exposed to in industrial environments. Additionally, the design of the AMT21 simplifies the assembly process, and the One Touch Zero(TM) feature allows time-consuming mounting and adjustment tasks to be completed in just a few seconds. With an operating temperature range of -40 to +105°C, high precision, a compact package, and low power consumption, the AMT21 is a powerful solution for various applications in industry, automation, robotics, and renewable energy.

• encoder

We developed a system that expands the functions of the electronic manifest ASP "KENET" to record the traceability from waste to the creation of recycled resources using blockchain technology. In May 2025, as a pre-service, we implemented registration functions from waste registration to the input of the recycling process and the completion of recycled resources. In January 2026, we newly developed functions for inventory management and shipping of recycled materials. The system also includes a CFP registration function for recycled resources, allowing for data input on the decarbonization effects of resource circulation. We aim to utilize the waste management functions cultivated over 18 years with KENET to advance into the field of resource circulation and work towards the effective use of waste for a circular society.

● This is a leak testing device for small electronic components that does not use fluorinated inert liquids (PFAS-free). ● There is no longer a need for unstable visual confirmation through liquid immersion testing. It adopts a quantitative testing method that allows for stable pressure leak testing. ● It is a tabletop leak testing device specifically for gross leaks, with accuracy equal to or greater than that of liquid immersion testing. ● The detectable range is approximately 1×10⁻² Pa·m³/s to 1×10⁻⁶ Pa·m³/s (varies depending on the target product). ● It is suitable for sealed structures ranging from a few millimeters to a maximum of 80 × 70 mm. Please feel free to contact us for more information!

The "Mechanical Stitching Method" by Nichinichisui Road Machinery Co., Ltd. is a new technique that allows for the repair of metal cracks without the application of heat. By using special bolts and reinforcement plates, cracks are physically removed, and repairs are made without causing any thermal impact to the base material. Repairs can be carried out in environments where open flames cannot be used. Since no heat is applied, the disassembly of equipment is minimized. ◎ For more details, please contact us. ◎ If you require a detailed technical explanation, please contact us.

The catalog subsidy is a grant system aimed at improving productivity and added value for small and medium-sized enterprises by selecting and implementing general-purpose labor-saving products such as IoT and robots from a pre-registered "product catalog." This initiative also aims to lead to wage increases. Features of the catalog subsidy: - Ability to choose general-purpose products from the catalog - Subsidy of up to 15 million yen - Support for applications from sales businesses - Ongoing public recruitment [Search for products that can be introduced with the catalog subsidy now] https://amada.shoryokuka-catalog.zeroplus-consul.co.jp/ *For more details, please refer to the related links or feel free to contact us.

Miami, Florida, January 10, 2026 - (JCN Newswire) - Promiscel, a clinical-stage cell immunotherapy company uniquely positioned in the development of potentially curative cell therapies for cancer patients, announced today that Dr. John Lee, our Chief Medical Officer, will present interim results of our lead asset, PRO CAR - 201A (a CAR T cell therapy targeting STEAP1). This therapy is currently being conducted as the first human Phase 1 clinical trial aimed at treating metastatic castration-resistant prostate cancer (mCRPC). The presentation will take place on January 12, 2025 (Monday) at 11:15 AM Pacific Standard Time at the Franciscan D (Ballroom Level) during the "Biotech Showcase 2026" in San Francisco, California.